Raymond James Financial’s Myriad Genetics MYGN Stock Holding History

Raymond James Financial’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,894	Closed	-$36.6K	–	6072
2025 Q2	$36.6K	Buy	+6,894	New	+$40.7K	﹤0.01%	5306

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's MYGN Position: Q3 2025 in Review

Raymond James Financial sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 6,894 shares — an estimated $36.6K sold.

Raymond James Financial first reported a position in MYGN in Q2 2025 and held it in 1 quarter. The position peaked at $36.6K in Q2 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

Raymond James Financial reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 6,894 Myriad Genetics shares in Q3 2025, an estimated $36.6K.
Raymond James Financial first reported a position in Myriad Genetics in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Myriad Genetics position peaked at $36.6K in Q2 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.